Yuh‐Min Chen - Concepedia

Author

Yuh‐Min Chen

Also Known As

Chao-Hsun Chen, Chen Yuh-Min, Chen, Yuh-Min, 1963-, Tsung-Yi Chen, Y M Chen, YUH-MIN CHEN, YUH‐MIN CHEN, Yuh-Jen Chen, Yuh-Min CHEN, Yuh-Min Chen

403

Publications

8.4K

Citations

H-Index

271

Concepts

All Affiliations

Taipei Veterans General Hospital National Yang Ming Chiao Tung University National Cheng Kung University National Taiwan University Hospital National University of Tainan

About

Yuh‐Min Chen is an author at Taipei Veterans General Hospital specializing in medicine, lung cancer, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	22	41	1.2K
2	Business	14	18	493
3	Health Sciences	12	12	394
4	Arts	5	5	144
5	Education	4	4	95

Yuh‐Min Chen

140

Publications

7.4K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, The Lancet OncologyAdjuvant ChemotherapyPathologyImmune Checkpoint InhibitorCancer Treatment	2021	1.4K
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer Teh‐Ying Chou, Chao‐Hua Chiu, Ling‐Hui Li, Clinical Cancer Research	2005	321
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial Yi‐Long Wu, Ying Cheng, Jianying Zhou, The Lancet Respiratory Medicine OncologyMet AmplificationMedicinePathologyPhase 1B/2	2020	249
Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) Jin Soo Lee, Vera Hirsh, Keunchil Park, Journal of Clinical Oncology	2012	231
Perceived barriers to physical activity among older adults residing in long‐term care institutions Yuh‐Min Chen Journal of Clinical Nursing	2010	181
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity Chao‐Hua Chiu, Chun‐Ming Tsai, Yuh‐Min Chen, Lung Cancer Brain MetastasesMedicineCancer ManagementImmunologyPathology	2004	143
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study Gee‐Chen Chang, Chao‐Hua Chiu, Chong‐Jen Yu, The Lancet Respiratory Medicine Tobacco ControlFamily MedicineCancer EpidemiologyMedical ImagingCancer Screening	2023	137
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Martin Schüler, James Chih‐Hsin Yang, K. Park, Annals of Oncology	2015	131
Non-small Cell Lung Cancer in Very Young and Very Old Patients Chih-Wei Kuo, Yuh‐Min Chen, Chun‐Ming Tsai, CHEST Journal Very YoungMedicineMultiple Pulmonary NodulePathologyPulmonary Blastoma	2000	120

Page 1